Functional Identification of Activity-regulated, High-affinity Glutamine Transport in Hippocampal Neurons Inhibited by Riluzole
Overview
Authors
Affiliations
Glutamine (Gln) is considered the preferred precursor for the neurotransmitter pool of glutamate (Glu), the major excitatory transmitter in the mammalian CNS. Here, an activity-regulated, high-affinity Gln transport system is described in developing and mature neuron-enriched hippocampal cultures that is potently inhibited by riluzole (IC 1.3 ± 0.5 μM), an anti-glutamatergic drug, and is blocked by low concentrations of 2-(methylamino)isobutyrate (MeAIB), a system A transport inhibitor. K -stimulated MeAIB transport displays an affinity (K ) for MeAIB of 37 ± 1.2 μM, saturates at ~ 200 μM, is dependent on extracellular Ca , and is blocked by inhibition of voltage-gated Ca channels. Spontaneous MeAIB transport is also dependent on extracellullar Ca and voltage-gated calcium channels, but is also blocked by the Na channel blocker tetrodotoxin, by Glu receptor antagonists, and by GABA indicating its dependence on intact neural circuits driven by endogenous glutamatergic activity. The transport of MeAIB itself does not rely on Ca , but on Na ions, and is pH sensitive. Activity-regulated, riluzole-sensitive spontaneous and K -stimulated transport is minimal at 7-8 days in vitro, coordinately induced during the next 2 weeks and is maximally expressed by days in vitro > 20; the known period for maturation of the Glu/Gln cycle and regulated pre-synaptic Glu release. Competition analyses with various amino acids indicate that Gln is the most likely physiological substrate. Activity-regulated Gln/MeAIB transport is not observed in astrocytes. The functional identification of activity-regulated, high-affinity, riluzole-sensitive Gln/MeAIB transport in hippocampal neurons may have important ramifications in the neurobiology of activity-stimulated pre-synaptic Glu release, the Glu/Gln cycle between astrocytes and neurons, and neuronal Glu-induced excitotoxicity. Cover Image for this issue: doi: 10.1111/jnc.13805.
Kyllo T, Allocco D, Hei L, Wulff H, Erickson J Front Pharmacol. 2024; 15:1466953.
PMID: 39539628 PMC: 11558044. DOI: 10.3389/fphar.2024.1466953.
Vazquez-Duran D, Ortega A, Rodriguez A Mol Neurobiol. 2024; 61(8):6077-6088.
PMID: 38273046 DOI: 10.1007/s12035-024-03966-3.
Erickson J, Kyllo T, Wulff H Curr Res Physiol. 2023; 6:100109.
PMID: 38107787 PMC: 10724208. DOI: 10.1016/j.crphys.2023.100109.
Neurotransmitters in Prevention and Treatment of Alzheimer's Disease.
Yang Z, Zou Y, Wang L Int J Mol Sci. 2023; 24(4).
PMID: 36835251 PMC: 9966535. DOI: 10.3390/ijms24043841.
Kyllo T, Singh V, Shim H, Latika S, Nguyen H, Chen Y Neuropharmacology. 2022; 224:109349.
PMID: 36436594 PMC: 9843824. DOI: 10.1016/j.neuropharm.2022.109349.